AU2001286557A1 - Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists - Google Patents

Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists

Info

Publication number
AU2001286557A1
AU2001286557A1 AU2001286557A AU8655701A AU2001286557A1 AU 2001286557 A1 AU2001286557 A1 AU 2001286557A1 AU 2001286557 A AU2001286557 A AU 2001286557A AU 8655701 A AU8655701 A AU 8655701A AU 2001286557 A1 AU2001286557 A1 AU 2001286557A1
Authority
AU
Australia
Prior art keywords
prostanoid
treating
receptor antagonists
urinary incontinence
preventing urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286557A
Inventor
Theodore P. Broten
Kathleen M. Metters
Francois J. Nantel
Mervyn Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Publication of AU2001286557A1 publication Critical patent/AU2001286557A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
AU2001286557A 2000-08-23 2001-08-20 Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists Abandoned AU2001286557A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22718300P 2000-08-23 2000-08-23
US60227183 2000-08-23
PCT/US2001/025982 WO2002015902A1 (en) 2000-08-23 2001-08-20 Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists

Publications (1)

Publication Number Publication Date
AU2001286557A1 true AU2001286557A1 (en) 2002-03-04

Family

ID=22852093

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286557A Abandoned AU2001286557A1 (en) 2000-08-23 2001-08-20 Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists

Country Status (3)

Country Link
US (1) US20020137746A1 (en)
AU (1) AU2001286557A1 (en)
WO (1) WO2002015902A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348486B1 (en) * 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
ITMI20010733A1 (en) * 2001-04-05 2002-10-05 Recordati Chem Pharm USE OF ISOENZIN COX-2 INHIBITORS FOR THE TREATMENT OF URINARY INCONTINENCE
JP2005526040A (en) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
WO2004074843A1 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep1 (prostaglandin e2 ep1)
GB0306329D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Compounds
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
BRPI0416157A (en) * 2003-11-03 2007-01-09 Boehringer Ingelheim Int pharmaceutical composition containing a beta-3 adrenoceptor agonist and an alpha antagonist and / or a 5-alpha reductase inhibitor
DE10356112A1 (en) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg A pharmaceutical composition of a beta-3 adrenoceptor agonist and a progglandin metabolite
US7858610B2 (en) * 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
EP1889612A3 (en) * 2006-07-24 2008-03-19 Jan Kees Piet Bruinstroop Method for controlling micturition
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
BRPI0807942A2 (en) 2007-02-16 2014-07-01 Ono Pharmaceutical Co THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER
CA2728098A1 (en) 2008-07-17 2010-01-21 Asahi Kasei Pharma Corporation Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor
CN102089303A (en) 2008-07-17 2011-06-08 旭化成制药株式会社 Nitrogenated heterocyclic compound
US9532959B2 (en) * 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10010514B2 (en) * 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CA2878478A1 (en) * 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
PL3203840T3 (en) 2014-10-06 2021-01-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US10738030B2 (en) 2016-03-31 2020-08-11 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2018064632A1 (en) 2016-09-30 2018-04-05 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2018107100A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
BR112019025801A2 (en) 2017-06-08 2020-07-07 Vertex Pharmaceuticals Incorporated treatment methods for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019028228A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
AU2018380426B2 (en) 2017-12-08 2023-05-18 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 Pharmaceutical compositions for treating cystic fibrosis
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108841A0 (en) * 1993-03-10 1994-06-24 Pfizer Res & Dev Benzopyrans
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives

Also Published As

Publication number Publication date
US20020137746A1 (en) 2002-09-26
WO2002015902A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
AU2001286557A1 (en) Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists
AU2001275257A1 (en) Methods and devices for the treatment of urinary incontinence
AU2002334833A1 (en) Urethral support for incontinence
MXPA03002276A (en) Urinary incontinence device and method of making same.
AU5204900A (en) Flushing method of toilet, toilet used for carrying out said method and components thereof
AU2001288825A1 (en) Bulking agent delivery method for treating incontinence
AU2002342707A1 (en) Combination of selected opioids with muscarine antagonists for treating urinary incontinence
AU2002336405A1 (en) Methods for treating deodorizer distillate
IL158050A0 (en) Use of selective cox-2 inhibitors for the treatment of urinary incontinence
AU7360700A (en) Methods and compositions for preventing and treating urinary tract disorders
AU2001243445A1 (en) Intra-urethral device for incontinence and method for making and using same
AU2002227449A1 (en) Control of urinary continence
AU2003214273A1 (en) Improved system for the treatment of stress urinary incontinence
HUP0200738A3 (en) Method of the treatment of incontinence
AU4552200A (en) Method of treating psychotic disorders
AU2002233210A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating urinary incontinence
AUPQ968700A0 (en) Treatment of urinary incontinence
AU2001233581A1 (en) Process for reserving and treating urine
AU2002223688A1 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
AU2002233209A1 (en) Use of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
HUP0303268A3 (en) Use of substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds for treating urinary incontinence
AU2001261513A1 (en) Composition and method for increasing testosterone levels
HUP0104514A2 (en) The use of aril-substituted cyclobutylalkylamines for treating urinary incontinence
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU1196601A (en) Methods of diagnosing and treating urinary incontinence